RETA
Reata Pharmaceuticals Inc
A biopharmaceutical company that developed SKYCLARYS (omaveloxolone), the first FDA-approved treatment for Friedreich's ataxia, a rare inherited neurodegenerative disease. Founded in 2002 with research pioneered at UT Southwestern and MD Anderson, it was originally called Reata Discovery before taking its current name in 2005. The name "Reata" is Spanish for a cowboy's lariat, and the company was acquired by Biogen in 2023.
CUSIP: 75615P103HealthcareUS1 holder
Total Value
$201.0K
Total Shares
2.0K
Net Share Change
0
Activity
No changes
Investor
Value
Shares
Weight
Change
